Elsevier

Kidney International

Volume 91, Issue 3, March 2017, Pages 539-551
Kidney International

Meeting Report
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

https://doi.org/10.1016/j.kint.2016.10.005Get rights and content
Under a Creative Commons license
open access

In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement plays a primary role in disease pathogenesis. Herein we report the outcome of a 2015 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference where key issues in the management of these 2 diseases were considered by a global panel of experts. Areas addressed included renal pathology, clinical phenotype and assessment, genetic drivers of disease, acquired drivers of disease, and treatment strategies. In order to help guide clinicians who are caring for such patients, recommendations for best treatment strategies were discussed at length, providing the evidence base underpinning current treatment options. Knowledge gaps were identified and a prioritized research agenda was proposed to resolve outstanding controversial issues.

Keywords

anti-complement therapies
atypical hemolytic uremic syndrome
C3 glomerulopathy
complement
glomerulonephritis
kidney disease

Cited by (0)

14

See Appendix for list of other conference participants.